CSIMarket
 
Healthcare Sector

In Vitro & In Vivo Diagnostic Substances Industry  




Data by Company within In Vitro & In Vivo Diagnostic Substances Industry


  Marketcap Revenues (TTM) Net Income (TTM) Employees
Company (Millions) (Millions) (Millions) Number
Idexx Laboratories Inc $ 44,504 $ 3,660 $ 845 10,350
Oncocyte Corporation $ 24,933 $ 6 $ -77 -
Ortho Clinical Diagnostics Holdings Plc $ 8,448 - $ 54 -
Lantheus Holdings Inc $ 3,971 $ 1,296 $ 327 1,000
Quidelortho Corp $ 3,278 $ 3,122 $ 13 -
Neogen Corporation $ 3,268 $ 918 $ -27 1,700
Intellia Therapeutics Inc $ 2,426 $ 52 $ -462 -
Celldex Therapeutics inc $ 1,984 $ 7 $ -141 -
Myriad Genetics Inc $ 1,791 $ 753 $ -263 2,700
Meridian Bioscience Inc $ 1,504 $ 339 $ 62 850
Heska Corporation $ 1,247 $ 255 $ -20 542
Mymd Pharmaceuticals Inc $ 128 - $ -5 -
Achieve Life Sciences Inc $ 97 - $ -36 -
Alpha Teknova Inc $ 85 $ 36 $ -39 -
Trinity Biotech Plc $ 73 $ 75 $ -41 569
Volitionrx Limited $ 68 $ 1 $ -34 -
Quotient Limited $ 39 $ 39 $ -136 -
Immucell Corp $ 39 $ 16 $ -6 -
Aspira Women s Health Inc $ 36 $ 9 $ -21 1,433
Arca Biopharma Inc $ 25 - $ -5 -
Lucira Health Inc $ 18 $ 212 $ -143 100
Nymox Pharmaceutical Corporation $ 18 $ 0 $ -7 -
Biomerica Inc $ 15 $ 5 $ -7 -
Navidea Biopharmaceuticals Inc $ 4 $ 1 $ -1 -
Burzynski Research Institute Inc $ 2 - $ -1 -
Cardio Diagnostics Holdings Inc - $ 6 $ -11 -
In Vitro & In Vivo Diagnostic Substances Industry $ 98,000 $ 10,799 $ -184 19,244
  Recent News from In Vitro & In Vivo Diagnostic Substances Industry
Clinical Study

The Phase 3 MAGNITUDE Study of NTLA-2001: A Promising CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, a renowned clinical-stage gene editing company, has recently commenced the global pivotal, Phase 3 MAGNITUDE trial of their investigational therapy, NTLA-2001. This single-dose, in vivo CRISPR-based treatment aims to inactivate the TTR gene, thereby preventing the production of TTR protein in patients with transthyretin (ATTR) amylo...

Product Service News

Trinity Biotech Overcomes Nasdaq Minimum Bid Price Rule, Fostering Investor Confidence

Trinity Biotech Regains Nasdaq Compliance Following Minimum Closing Bid Price RuleDUBLIN, Ireland - Trinity Biotech Plc. (NASDAQ: TRIB) announced today that it has successfully regained compliance with the minimum closing bid price requirement set by The Nasdaq Stock Market. The company had received a formal notification from Nasdaq regarding its complian...

Announcement

QuidelOrtho Faces Potential Securities Class Action Investigation by Rosen Law Firm, Raising Concerns for Shareholders

In recent news, the highly reputable law firm, Rosen Law Firm, has urged investors of QuidelOrtho Corporation (NASDAQ: QDEL) to participate in an ongoing securities class action investigation. The investigation aims to determine if QuidelOrtho has potentially provided misleading business information, which may have caused significant harm to shareholders....

Product Service News

Lantheus Expands DEFINITY's Reach with FDA Approval for Pediatric Patients, Solidifying its Position as the Leading Ultrasound Enhancing Agent for Suboptimal Echocardiograms in the U.S.

Lantheus Announces FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients; Solidifies its Position as the Leading Ultrasound Enhancing Agent for Suboptimal Echocardiograms in the U.S.In a recent press release, Lantheus, a global leader in diagnostic imaging, announced the much-anticipated approval of DEFINITY (Perflutren Lipid Micr...

Announcement

Investigating QuidelOrtho Corporation: Potential Securities Claims Arise Amid Allegations of Misleading Business Information

Investigation Underway for Potential Securities Claims against QuidelOrtho CorporationIn the rapidly evolving world of investments, investors rely heavily on accurate and reliable information when making decisions about where to allocate their funds. With this in mind, it is concerning to hear allegations that QuidelOrtho Corporation may have issued misl...

Stock Market Announcement

Celldex Therapeutics Raises Impressive $400 Million in Upsized Public Offering

Celldex Therapeutics Announces Pricing of Upsized Public Offering, Expected to Raise $400.4 Million
Celldex Therapeutics, Inc. (Celldex), a biopharmaceutical company focused on developing targeted immunotherapies for the treatment of cancer and other diseases, made a significant announcement today regarding the pricing of an upsized underwritten publi...

Product Service News

Achieve Life Sciences Nears FDA Approval Milestone for Groundbreaking Smoking Cessation Compound, Cytisinicline

In a significant development, Achieve Life Sciences recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the requirements for long-term exposure data on Cytisinicline, a promising compound for smoking cessation. The agreement marks a major step forward for Achieve Life Sciences as it m...

Management Announcement

Achieve Life Sciences' $124.2 Million Offering Aims to Address Financial Struggles Amidst Challenging Competition

Achieve Life Sciences Announces $124.2 Million Offering Amidst Accumulating Losses and Challenging Competition
Achieve Life Sciences Inc has made headlines once again, this time with its recent pricing of a registered direct offering and concurrent private placement, aiming to raise up to $124.2 million. This considerable financing effort involves a...

Myriad Genetics Inc

Revolutionizing Cancer Monitoring: Myriad Genetics Inc. Makes Strides in MRD Research and Financial Performance for Q4 2023

r/>Myriad Genetics Inc., a leading molecular diagnostics company, recently announced its participation in an innovative clinical trial that aims to transform the way we monitor minimal residual disease (MRD) across different types of cancer. This collaboration with the National Cancer Center Hospital East in Japan marks a significant milestone in cancer r...

Shares

Celldex Therapeutics Proposes a $250 Million Public Offering, Signaling Confidence in Future Growth and Advancement of Innovative Product Candidates


Hampton, N.J., Feb. 28, 2024 - Celldex Therapeutics, Inc. (Nasdaq: CLDX) has recently announced its proposal to offer and sell shares of common stock in an underwritten public offering, with an added option for underwriters to purchase additional shares. This move comes in line with the company's commitment to continue clinical and preclinical develo...







Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com